RichardThomasMaziarzMD

Oncology • Portland, OR

Hematologic Oncology

Medical Director, Adult Stem Cell Transplant Program; Professor, Oregon Health & Science University

Join to view full profile

Dr. Maziarz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maziarz's full profile

Already have an account?

Office
3181 SW Sam Jackson Park Rd
# Mail
Portland, OR 97239
Phone+1 503-494-4606

Fax+1 503-494-1552

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1987
Harvard Medical SchoolClass of 1979

Certifications & Licensure

HI State Medical License 2024 - 2026
OR State Medical License 1992 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Portland Monthly Magazine Castle Connolly, 2011
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Join now to see all

Clinical Trials

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 3
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Start of enrollment: 2005 Mar 01
Completed
Phase 2
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 1, Phase 2
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML Start of enrollment: 2003 May 01
Terminated
Phase 2
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia Start of enrollment: 2008 Jul 01
Completed
Phase 1
Fosaprepitant for Breakthrough Chemotherapy Induced Nausea and Vomiting Start of enrollment: 2009 Dec 01
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Start of enrollment: 2013 Mar 01
Active, not recruiting
Phase 1, Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies Start of enrollment: 2020 Jul 08
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

The rationale behind grafting haploidentical hematopoietic stem cells.
Richard T Maziarz, Rachel J Cook
Hematology. 2024-12-01
A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques.
Helen L Wu, Whitney C Weber, Courtney M Waytashek, Carla D Boyle, Jason S Reed
Plos Pathogens. 2024-11-01
1 citations
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Nausheen Ahmed, William Wesson, Forat Lutfi, David L Porter, Veronika Bachanova
Blood Advances. 2024-10-22

Abstracts/Posters

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Monkey Model Offers Clues for Potential Widespread HIV Cure in PeopleMay 25th, 2023
Research Offers Clues for Potential Widespread HIV Cure in People: New Study Reveals First Details on How Stem Cell Transplantation Can Kill Virus That Causes AIDSMay 25th, 2023
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health EquityApril 25th, 2022
Join now to see all